Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands

Vaccine

Volumn 29, Issue 28, 2011, Pages 4601-4607

  Klooster, T M Van't ^a   Kemmeren, J M ^a   Van Der Maas, N A T ^a   De Melker, H E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adverse events following immunization; HPV vaccination; Human papillomavirus; Tolerability

Indexed keywords

ANALGESIC AGENT; PARACETAMOL; WART VIRUS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ARM; ARTHRALGIA; ARTICLE; ASTHMA; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMMON COLD; CONTROLLED STUDY; COUGHING; CRYING; DIABETES MELLITUS; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; E-MAIL; ECZEMA; FATIGUE; FEMALE; FEVER; HAY FEVER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFLUENZA; LISTLESSNESS; MAJOR CLINICAL STUDY; MUSCLE CONTRACTION; MYALGIA; NAUSEA; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN REDNESS; SLEEP DISORDER; SWEATING; SWELLING; SYNCOPE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VOMITING; WEB BROWSER;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERNET; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUESTIONNAIRES; VACCINATION;

EID: 79958128068     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.050     Document Type: Article

References (19)

1. Dutch Health Council Vaccination against cervical cancer 2008, Dutch Health Council, The Hague, Publication No.: 2008/08. Dutch.
2. de Melker H.E., Conyn-van Spaendonck M.A.E., Boot H.J., Coutinho R.A. Introduction of vaccination against cervical cancer. Ned Tijdschr Geneeskd 2009, 153:A67. [Dutch].
3. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(June (9580)):2161-2170.
4. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40(June (6)):564-571.
5. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(November (9447)):1757-1765.
6. Kim Y.J., Kim K.T., Kim J.H., Cha S.D., Kim J.W., Bae D.S., et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci 2010, 25(August (8)):1197-1204. [Epub 2010 July 21].
7. Medina D.M., Valencia A., de Velasquez A., Huang L.M., Prymula R., García Sicilia J., et al. HPV-013 Study Group. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010, 46(May (5)):414-421.
8. Petäjä T., Keränen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44(January (1)):33-40.
9. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(March (3)):201-209.
10. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Females united to unilaterally reduce endo/ectocervical disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
11. Marcy S.M., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22(January (5-6)):551-556.
12. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002, 21(December (3-4)):298-302.
13. Kemmeren JM, van der Maas NA, de Melker HE. Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. Eur J Pediatr Epub 2010 September 21.
14. Vermeer-de Bondt P.E., van der Maas N.A. The effect of age and dose number on the risk of collapse (hypotonic-hyporesponsive episode) after pertussis vaccination. Pediatr Infect Dis J 2008, 27(April (4)):355-357.
15. Halperin S.A., Scheifele D., Mills E., Guasparini R., Humphreys G., Barreto L., et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003, 21(June (19-20)):2298-2306.
16. Gold M.S., Noonan S., Osbourn M., Precepa S., Kempe A.E. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003, 179(August (4)):191-194.
17. Jacquet J.M., Bégué P., Grimprel E., Reinert P., Sandbu S., Silfverdal S.A., et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 2006, 24(March (13)):2440-2448.
18. David S., Vermeer-de Bondt P., van der Maas N. Increase in localised symptoms in 4-year-olds following revaccination with DaPT-IPV. Ned Tijdschr Geneeskd 2010, 154(A980). [Dutch].
19. van't Klooster TM, Kemmeren JM, Vermeer-de Bondt PE, Oostvogels B, Phaff T, de Melker HE, et al. Human papillomavirus vaccination catch-up campaign in 2009 for girls born in 1993-1996 in the Netherlands: results of the post-marketing safety surveillance. Bilthoven; 2011. Report No.: 210012001.